Carol A. Schafer
Independent DirectorMs. Carol A. Schafer is Non-Executive Director at OMass Therapeutics Limited since August 2025. She serves as an Independent Director of Immunome, Inc. since January 2, 2024 and also serves as Independent Director at Kura Oncology, Inc. since June 03, 2021. She has been a Director of Insmed Incorporated since April 1, 2020 and was Independent Director at Idera Pharmaceuticals, Inc. since December 18, 2018 until September 2022. She served as an Independent Director of Five Prime Therapeutics, Inc. since May 15, 2019 until April 16, 2021. Ms. Schafer has been an Independent Director of Repare Therapeutics Inc. since March 2019. Ms. Schafer is a consultant in the biotech industry. She is a seasoned financial professional with experience in investment banking and equity capital markets, as well as corporate finance and business development in the biopharmaceutical sector, with substantial experience financing and facilitating investor access for public and private healthcare companies. Ms. Schafer serves as a Managing Partner at Hyphen Advisors, LLC since 2018. Prior to Hyphen Advisors, Ms. Schafer Managing Director of Equity Capital Markets Business at Wells Fargo Advisors (Wachovia Securities). since April 2007. Ms. Schafer previously spent 17 years at JP Morgan, as Managing Director and Equity Capital Markets Industry Group Leader for the healthcare team. Immediately prior to joining Wachovia, Ms. Schafer was Vice President of Finance and Business Development at Lexicon Genetics, a biotechnology company. Prior to Wells Fargo, Ms. Schafer served as Vice President of Finance and Business Development at Lexicon Pharmaceuticals from December 2003 to February 2007. In her career, Ms. Schafer served as an Equity Capital Markets Sector Head in her role as a Managing Director and Vice President at J.P. Morgan from 1986 till 2003. Ms. Schafer received Bachelor of Arts in mathematics and computer science from Boston College and an M.B.A from New York University’s Stern School of Business.
Positions
- Company NameInsmed IncorporatedStock CodeINSMPositionIndependent DirectorColleagues
- WHWilliam H. LewisPresident, CEO & Chairman
- RARoger AdsettChief Operating Officer
- MAMichael Alexander SmithChief Legal Officer & Corporate Secretary
- MFMartina FlammerChief Medical Officer
- BOBrendan O’LearySenior Vice President of Finance
- DRDavid R. BrennanLead Independent Director
- MSMelvin SharokyIndependent Director
- LLLeo LeeIndependent Director
- Company NameImmunome, Inc.Stock CodeIMNMPositionIndependent DirectorColleagues
- CBClay B. SiegallChairman, President & CEO
- MRMax RosettChief Financial Officer
- RJRobert J. LechleiderChief Medical Officer
- PTPhilip TsaiChief Technical Officer
- JHJack HigginsChief Scientific Officer
- IBIsaac BarchasLead Independent Director
- JPJames Patrick BoylanIndependent Director
- CACarol A. SchaferIndependent Director
- PWPhilip WagenheimIndependent Director
- Company NameKura Oncology, Inc.Stock CodeKURAPositionIndependent DirectorColleagues
- TETroy Edward WilsonChairman, CEO & President
- KFKathleen FordChief Operating Officer
- BTBrian T. PowlChief Commercial Officer
- JFJennifer FulkChief Financial Officer
- TDThomas DoyleSenior Vice President of Finance & Accounting
- KMKevan M. ShokatChairman of the Scientific Advisory Board
- TRThomas Robert MalleyIndependent Director
- MTMary T. SzelaIndependent Director
- CACarol A. SchaferIndependent Director
